SEATTLE (December 18, 2012) – Etubics Corporation, a clinical stage bio-pharmaceutical company with a proprietary platform vaccine technology that delivers a long lasting “active” immune response against diseases, announced that Vaccine has published a peer reviewed publication entitled, “Control of SIV Infection and Subsequent Induction of Pandemic H1N1 Immunity in Rhesus Macaques Using an Ad5[E1 -, E2b-] Vector Platform.”
Etubics has developed a novel delivery platform, Ad5[E1-,E2b-], that induces an immune response despite pre-existing and/or developed Ad5 immunity. Rhesus macaques (RM) were immunized against two separate disease targets, SIV and H1N1, and Etubics was able to overcome Ad5 immunity to induce effective immune responses against both infectious diseases in the same animal.
Ad5 immune RMs were immunized multiple times with the Ad5 [E1-, E2b] expressing antigens from simian immunodeficiency virus (SIV), the RM equivalent of HIV. Immunized RM developed cellmediated immunity against the SIV antigens. Vaccinated and vector control RMs were then challenged with SIV. At a seven week post-challenge follow-up, 53% of the immunized animals did not have detectable SIV, compared to 13% in the control group.
The RM without detectable SIV, now hyper immune to Ad5, were then vaccinated with the same Ad5 [E1-, E2b] platform expressing H1N1 influenza hemagglutinin (HA). Thirty days post vaccination, significant levels of influenza neutralizing antibody were induced in all RMs which increased after an Ad5 [E1-, E2b]- HA boost.
Dr. Frank R. Jones, founder, Chairman and Chief Executive Officer of Etubics stated, “In this preclinical study, we were able to overcome an issue that has been plaguing scientists for quite some time, overcoming Ad immunity. Not only are we excited about overcoming both SIV and H1N1 in the same animal utilizing the Etubics Platform, but we are also excited that we have overcome an issue that has kept Ad products at the research level.”
To view the publication online, visit http://www.ncbi.nlm.nih.gov/pubmed/23041546.
Etubics is developing the next generation in vaccines and immunotherapies, utilizing a patented advanced generation adenovirus delivery platform and a validated manufacturing human cell line, collectively the Etubics Platform. Etubics will be entering a Phase IIb clinical trial with an immunotherapeutic product candidate to treat advanced colorectal cancer in early 2013. Etubics preclinical HIV work has been fully funded through grants from the National Institute of Allergy and Infectious Diseases (NIAID). The NCI has also awarded earlier grants to Etubics for its colorectal and breast cancer pre-clinical and colorectal clinical work.
Etubics Corporation, based in Seattle, Wash., is a next generation clinical stage bio-pharmaceutical company, which has developed a proprietary platform technology consisting of a next generation Adenovirus Vector Vaccine Platform and a manufacturing E.C7 human cell line, collectively the Etubics Platform. Clinical work to date shows that the Etubics Platform overcomes problems associated with existing adenovirus vectors. The Company’s Platform can be used to efficiently and rapidly develop immunotherapeutic drugs and preventive vaccines for a wide range of infectious diseases and cancers .
Statements herein relating to future financial, business performance, conditions or strategies and other financial and business matters, including expectations regarding future revenues and operating expenses, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act. Etubics is a private company. Etubics cautions that these forward-looking statements are subject to numerous assumptions, risks and uncertainties which change over time. Factors that may cause actual results to differ materially from the results discussed in the forward looking statements or historical experience include risks and uncertainties, including the failure by Etubics to secure and maintain relationships with collaborators; risks relating to the early state of Etubics’s product candidates under development; uncertainties relating to clinical trials and regulatory requirements and actions; risks relating to the commercialization, if any, of Etubics proposed product candidates; competitive risks to marketed products; dependence on the efforts of third parties; dependence on intellectual property; and risks that it may lack the financial resources and access to capital to fund its operations. Further information on the factors and risks that could affect Etubics’s offices, business, financial conditions and results of operations, are contained in Etubics’s documents on file at the Company. These forward-looking statements speak only as of the date of this press release and Etubics assumes no duty to update forward-looking statements.
Investor/Media contact: Ms. Ines Tucakovic Clark Phone: (206) 838-5110 Ext. 110 firstname.lastname@example.org